Introduction
Primary gallbladder cancer (GBC) is a rare malignancy of the digestive system ranking sixth most common, however it is the most common malignancy of the biliary tract, accounting for 80–95% of biliary tract cancers. In 2008, it accounted for an estimate of 1.1% of all newly diagnosed cancer cases, ranking 16th amongst all types of tumors; furthermore, it accounted for 1.4% of all cancer-associated mortalities, ranking 9th amongst all cancers (1). Due to its high degree of malignancy and few effective therapeutic options, the prognosis of GBC patients is currently poor. In recent years, the incidence of GBC has increased in northern India, Pakistan and Korea (1,2). As GBC has no specific clinical symptoms at the early stage, the majority of patients are diagnosed at the advanced stage, at which palliative treatment is the only option. Therefore, the five-year survival rate for GBC is only ~10% (3). While chemotherapy is the major treatment option for patients at advanced cancer stages, GBC is resistant to standard cytotoxic drugs, and no effective chemotherapeutic options are available at present (4). Hence, it is required to discover novel drugs or means of sensitizing GBC cells to chemotherapeutics, and to explore novel therapeutic strategies and improved diagnostics.
In 1972 Chinese scientists extracted an effective antimalarial component from Artemisia annua L, named artemisinin (qinghaosu). Artemisinin belongs to the new sesquiterpene lactone drugs and contains an endoperoxide moiety, and its derivatives include dihydroartemisinin, artemether, arteether and artesunate (5,6). Traditional antimalarial drugs such as quinoline have been replaced with artemisinin due to its lower toxicity and higher antimalarial activities, and artemisinin has become the preferred drug of the World Health Organization for treating Plasmodium falciparum infection and cerebral malaria. Studies have revealed that besides its anti-parasitic effects, artemisinin possessed further pharmacological activities, including anti-inflammatory, antitumor and immunomodulatory effects. The molecular mechanisms of the anticancer effects of artemisinin are complex. It has been demonstrated that artemisinin inhibits tumor proliferation, angiogenesis, invasion and metastasis, induces cell cycle arrest and apoptosis, reverses multidrug resistance and sensitizes cancer cells to chemotherapy (7). A number of studies have shown that artemisinin and its derivatives inhibit the growth of colon cancer (8), ovarian cancer (9), lymph node metastasis of lung cancer cells (10), breast cancer (11), hepatocellular carcinoma (12) and prostate cancer (13) in vivo or in vitro, while its efficacy against gallbladder cancer cells has not been reported. Therefore, the present study was performed to examine the effects of artemisinin on the proliferation, cell cycle and apoptosis of the gallbladder cancer cell lines GBC-SD and NOZ and to explore the underlying molecular mechanisms.
Materials and methods
Cell culture
The GBC-SD and NOZ gallbladder cancer cell lines were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan). Cell lines were maintained at 37°C in Dulbecco's modified Eagle's medium (DMEM; Gibco, Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO, USA), 1 mM non-essential amino acids (Sigma-Aldrich) and 1% penicillin/streptomycin (Sigma-Aldrich) at 37°C in a humidified atmosphere containing 5% CO2. Cells were divided and subcultured upon reaching 80% confluence and passaged with 0.25% trypsin (Gibco).
Cell proliferation assay
Cells cultured in the presence or absence of artemisinin were subjected to a viability assay using the WST-1 cell proliferation reagent (Roche, Mannheim, Germany). In brief, 5×103 cells were seeded into each well of a 96-well plate and incubated for attachment overnight. Artemisinin was added to the wells resulting in the following concentrations: 0, 2.5, 5, 10, 20, 40, 80 and 160 µM, and cells were incubated for 48 h. The wells were subsequently washed once with 100 µl phosphate-buffered saline (PBS). DMEM (100 µl) containing 10% FBS was placed in the wells, followed by 10 µl WST-1 diluted 1:10 in culture medium. Following incubation for 2 h, the optical density (OD) at 450 nm was measured using a Model 550 microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Cell survival rates were calculated using the following equation: (ODExperimental group)/(ODControl group) × 100%.
Xenograft study
To evaluate the effects of artemisinin on gallbladder tumors in vivo, GBC-SD and NOZ-derived xenograft mouse models were used. All animal procedures were approved by the Ethical Commission of the First Affiliated Hospital of Bengbu Medical College (Bengbu, China). Male BALB/c nude mice (n=24; age, 5 weeks; weight, 250–300 g) were obtained from Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China) and raised under specific pathogen-free conditions. They were maintained in conditions of 21°C and 50% humidity, under a 12-h light/dark cycle. Mice had free access to food and water. After one week, 1×107 GBC-SD or NOZ cells were subcutaneously injected into the right flank of each mouse (n=12 in each group) following anesthesia with isoflurane (Merck Millipore, Darmstadt, Germany). Tumors had formed in all mice after two weeks. When tumors reached a volume of ~0.5 cm3, the mice were orally administered artemisinin (100 mg/kg per day; dissolved in drinking water and delivered by oral gavage) or a control over 30 days. The tumor dimensions were measured every five days using a CD-6 CS caliper (Mitutoyo Corporation, Kawasaki, Japan), and the tumor volume was calculated according to the following modified ellipsoidal formula: Tumor volume = 1/2(length × width2). On day 30 of artemisinin administration, mice were anesthetized with isoflurane prior to sacrifice by cervical dislocation, and tumors were weighed.
Western blot analysis
Western blotting was used to determine the levels of certain proteins. GBC-SD and NOZ cells were treated with 20µM artemisinin for 24 h. Total protein was extracted using the Cell Lysis Buffer for Western and IP (Beyotime Institute of Biotechnology, Haimen, China) according to the manufacturer's protocols and the protein concentration of the extract was determined using the Bradford Protein assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Equal amounts (25 µg) of protein samples were separated using 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (Beyotime Institute of Biotechnology) and transferred onto a 0.2-µm polyvinylidene difluoride membrane (EMD Millipore, Billerica, MA, USA). The membrane was blocked in 5% non-fat milk. Membranes were probed with primary antibodies overnight at 4°C. The primary antibodies used were as follows: Polyclonal rabbit anti-phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK1/2; 1:200; Santa Cruz Biotechnology, Inc., Dallas, TX, USA; cat. no. sc-23759); monoclonal mouse anti-p16 (1:100; Santa Cruz Biotechnology, Inc.; cat. no. sc-377412); mouse monoclonal anti-β-actin (1:200; Santa Cruz Biotechnology, Inc.; cat. no. sc-47778); mouse monoclonal anti-cyclin D kinase (CDK)4 (1:200; Santa Cruz Biotechnology, Inc.; cat. no. sc-23896); mouse monoclonal anti-cyclin D1 (1:200; Santa Cruz Biotechnology, Inc.; cat. no. sc-20044); polyclonal rabbit anti-caspase-3 (1:200; Santa Cruz Biotechnology, Inc.; cat. no. sc-7148); polyclonal rabbit anti-poly(adenosine diphosphate ribose) polymerase (PARP)-1 (1:200; Santa Cruz Biotechnology, Inc.; cat. no. sc-7150); mouse monoclonal anti-cytochrome c (1:200; Santa Cruz Biotechnology, Inc.; cat. no. sc-65396); and mouse monoclonal anti-cycloxygenase IV (1:100; Santa Cruz Biotechnology, Inc.; cat. no. sc-376731). The membranes were then washed three times in Tris-buffered saline containing Tween 20 (TBST), incubated with goat anti-mouse (1:2,000; Santa Cruz Biotechnology, Inc.; cat. no. sc-2005) or anti-rabbit horseradish peroxidase antibody (1:5,000; Santa Cruz Biotechnology, Inc.; cat. no. sc-2004) for 1 h at room temperature and then washed three times in TBST. Protein signals were visualized using an enhanced chemiluminescence solution (ECL Plus; GE Healthcare, Little Chalfont, UK) and blots were exposed to X-Omat LS film (Eastman Kodak Co., Rochester, NY, USA). Cyclooxygenase IV and β-actin were used as the cytoplasmic and mitochondrial marker, respectively.
Cell cycle analysis
To determine the effect of artemisinin on the cell cycle of gallbladder cancer cells, GBC-SD and NOZ cells were seeded in a six-well plate and incubated overnight for attachment. Artemisinin (20 µM) was added to the wells of the plates for 24 h. After two washes with PBS, the cells were fixed in 70% pre-cooled ethanol for 12 h. The cells were then treated with RNase A (50 µg/ml; Sigma-Aldrich) and stained with propidium iodide (PI; EMD Millipore, Billerica, MA, USA) according to the manufacturer's instructions. Samples were analyzed on a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and their DNA content was analyzed using ModFit LT software (version 3.1; Verity Software House, Topsham, ME, USA).
Apoptosis assay
Annexin V-fluorescein isothiocyanate (FITC)/PI staining (BD Biosciences) was used for apoptosis analysis. In brief, cells were treated with artemisinin (20 µM) for 24 h, harvested, rinsed with cold PBS and resuspended in Annexin V-FITC binding buffer at a final density of 1×105 cells/ml. Annexin V-FITC (5 µl) and 50 µg/ml PI (10 µl) were added to 195 µl of the cell suspension. The cell suspension was gently vortexed and then incubated for 15 min at room temperature protected from light. Subsequently, samples were analyzed using a FACSCalibur flow cytometer within 1 h.
Mitochondrial membrane potential (Δψm) assay
Loss of Δψm is a fundamental early event in the apoptotic process. The reagent 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimid-azolcarbocyanine iodide (JC-1) is one of the most specific agents for measuring changes in Δψm. The high Δψm of normal cells loaded with JC-1 allows for the formation of J-aggregates, which exhibit red fluorescence. Upon loss of Δψm, the J-aggregates dissociate into monomers, leading to a shift in fluorescence wavelength from red to green. Therefore, JC-1 was used to assess changes in Δψm in the present study. This assay was performed with the JC-1 mitochondrial membrane potential detection kit (Biotium, Inc., Hayward, CA, USA). Cell suspension containing 5×105 cells was centrifuged at 500 × g for 5 min at room temperature and the cells were resuspended in 0.5 ml JC-1 working solution at 37°C for 15 min. Cells were then rinsed in 2 ml 1X JC-1 staining buffer twice and resuspended in the same buffer prior to analysis by flow cytometry. The fluorescence intensity of JC-1 was measured by flow cytometry (FACSCalibur) with an excitation wavelength of 490 nm and an emission wavelength of 530 nm for JC-1 monomers, and an excitation wavelength of 525 nm and an emission wavelength of 590 nm for JC-1 aggregates.
Measurement of intracellular reactive oxygen species (ROS)
A 2′,7′-dichlorofluorescein diacetate (DCFH-DA) assay was used to measure intracellular ROS production. DCFH-DA diffuses passively through the cellular membrane and is hydrolyzed by intracellular esterase to the non-fluorescent DCFH. In the presence of ROS, DCFH can be oxidized to the highly fluorescent DCF. After incubation with artemisinin (20 µM) for 24 h, cells were treated with DCFH-DA (10 µM in serum-free medium; Sigma-Aldrich) at 37°C for 30 min. The fluorescence intensity of DCF was measured using a fluorescence microplate reader with an excitation wavelength of 488 nm and an emission wavelength of 525 nm.
Statistical analysis
All statistical analyses were performed by using SPSS 14.0 (SPSS, Inc., Chicago, IL, USA). Values are expressed as the mean ± standard deviation. For comparison of the means of two groups, the independent samples t-test was used. For comparison of the magnitude of changes among three or more groups, one-way analysis of variance was used. All experiments of the present study were performed independently at least three times.
Results
Artemisinin inhibits the proliferation of GBC cells in vitro and in vivo
First, the effects of artemisinin on the proliferation of GBC cells were assessed in vitro. A WST-1 assay showed that at concentrations of 20-160 µM, artemisinin concentration-dependently inhibited the proliferation of GBS-SD and NOZ cells (P<0.05) (Fig. 1A and B). The IC50 values of artemisinin were 49.14±1.69 and 58.60±1.77 µM for GBS-SD and NOZ cells, respectively.
In the xenograft experiment, artemisinin showed a significant inhibitory effect on GBC cell-derived tumors in vivo. From treatment day 15 onwards, mice treated with artemisinin began to show a significantly reduced tumor volume compared with that of the control mice (P<0.05) (Fig. 1C and D). The weight of tumors grown in mice treated with artemisinin was also significantly lower than that in the control animals (P<0.05) (Fig. 1E and F).
In addition, western blot analysis showed that after 24 h of treatment with artemisinin, the protein levels of p-ERK1/2 were obviously decreased in GBC-SD and NOZ cells. (Fig. 1G).
Artemisinin induces G1-phase arrest in GBC-SD and NOZ cells via downregulation of CDK4 and cyclin D1 and upregulation of p16
The effects of artemisinin on the cell cycle of gallbladder cancer cells were further examined. As shown in Fig. 2A–C, the proportion of cells in G1 phase was significantly increased after treatment with artemisinin when compared with that of the controls (P<0.05). Furthermore, the expression of cell cycle-associated proteins was analyzed by western blot. After treatment with artemisinin, the expression of CDK4 and cyclin D1 was significantly decreased, while p16 showed a marked increase (Fig. 2D).
Artemisinin induces apoptosis of GBC-SD and NOZ cells through activation of caspase-3
The effects of artemisinin on apoptosis of GBC cells were then assessed. The apoptotic rates of GBC-SD and NOZ cells are shown in Fig. 3A–C. The proportion of apoptotic cells was significantly increased following treatment with 20 µM artemisinin for 24 h compared to that in the control group (P<0.05). Furthermore, the effect of artemisinin on the levels of cleaved caspase 3 and cleaved PARP were detected, indicating that caspase 3 and PARP were activated by artemisinin in GBC-SD and NOZ cells (Fig. 3D).
Artemisinin induces Δψm collapse of GBC-SD and NOZ cells via cytochrome c release
Furthermore, the present study examined the effects of artemisinin on mitochondrial functions of GBC-SD and NOZ cells. As shown in Fig. 4A–C, the red/green fluorescence ratio was high in untreated GBC-SD and NOZ cells. However, the addition of 20 µM artemisinin caused a reduction of the red/green fluorescence ratio, which reflected the collapse of the Δψm in artemisinin-treated cells. Immunoblotting of cell extracts showed decreased mitochondrial cytochrome c in cells treated with 20 µM artemisinin, while cytoplasmic cytochrome c was significantly increased (Fig. 4D), suggesting that artemisinin promotes cytochrome c release from mitochondria to cytoplasm.
Artemisinin induces the generation of ROS
As mitochondrial functions are tightly associated with ROS generation, the present study further examined the effect of artemisinin on the generation of ROS in GBC-SD and NOZ cells. As shown in Fig. 5, cells treated with artemisinin exhibited a significantly higher ROS-associated fluorescence intensity. It was therefore indicated that artemisinin can promote the generation of ROS.
Discussion
The five-year survival rate of GBC patients is currently low due to insufficient diagnostic tools and inefficient treatment strategies as well as the occurrence of drug resistance. Therefore, it is urgently required to explore novel and effective therapeutic options for patients with gallbladder cancer.
The aim of the present study was to assess the potency of artemisinin, a pharmaceutically approved drug currently used for the treatment of malaria and which has been demonstrated to have inhibitory effects on a variety of cancer types, against GBC and to explore the underlying molecular mechanisms. It was demonstrated that artemisinin inhibited GBC cell proliferation in vitro and in vivo, inhibited the cell cycle and induced apoptosis, likely through the generation of ROS.
Studies have shown that artemisinin inhibits the proliferation of numerous tumor cell types (8–13). The present study was the first to reveal that artemisinin also inhibited the proliferation of the GBC cell lines GBC-SD and NOZ. An in vitro cell viability demonstrated that and artemisinin (20–160 µM) exerted its growth inhibitory effects in a concentration-dependent manner. The calculated IC50 values for GBC-SD and NOZ cells were 49.14±1.69 and 58.60±1.77 µM, respectively. In addition, artemisinin showed significant inhibitory activity against GBC cell-derived tumors in a murine xenograft model.
The PI3K/Akt/ERK1/2 signaling pathway is critical in cell proliferation and apoptosis (14). ERK1/2 is highly expressed or constitutively activated in a variety of tumor types, including gallbladder cancer (15,16). Inhibition of ERK1/2 expression or activity can suppress tumor cell proliferation (17). The present study revealed that cells treated with artemisinin reduced the expression of p-ERK1/2, indicating that the inhibition of cell proliferation by artemisinin may by dependent on the suppressed activation of the ERK1/2 signaling pathway.
It has been indicated that artemisinin and its derivatives may inhibit tumor cell proliferation through blocking the cell cycle. Studies have shown that the drugs can induce cell cycle arrest at the different phases, such as G1-phase arrest in Ishikawa endometrial carcinoma (18), MCF7 breast cancer (19), A431 skin cancer (20) and LNCaP prostate cancer (21) cells, or G2/M phase arrest in A549 non-small cell lung cancer (22), H69 small cell lung cancer, HCT116 colon cancer and U251 glioma cells (23). These data suggested that the cell cycle regulatory effect of artemisinin and its derivatives is cell type specific, possibly due to differences in the regulation of certain key cell cycle regulators. However, the effect of artemisinin on the cell cycle of GBC cell lines has not been previously reported. The present study revealed that artemisinin induced G1-phase arrest in GBC-SD and NOZ cells. To examination of the underlying molecular mechanisms, the levels of certain cell cycle regulatory proteins were assessed. As is known, the transformation from G1 phase to S phase is a key step during cell cycle progression, and the G1/S checkpoint is regulated by multiple proteins. CDKs, the key regulators of cell cycle progression, can be activated during a specific cell cycle phase and subsequently form complexes with cyclins such as the CDK4/6-cyclin D1 complex, which triggers downstream events that promote cell cycle progression. The cyclin-dependent kinase inhibitor protein p16 can competitively bind with CDK4/6 to inhibit its activation and block cell cycle progression by triggering G1 arrest (24). The present study revealed that artemisinin treatment upregulated the expression of p16 protein while downregulating CDK4 and cyclin D1 expression, suggesting that artemisinin may induce G1-phase arrest by regulating the p16/CDK4/cyclin D1 pathway.
Besides induction of cell cycle arrest, artemisinin can also inhibit tumor cell proliferation via induction of apoptosis (25–27). Studies have shown that artemisinin can activate the p53-dependent and p53-independent apoptotic pathway (28–30), and that active oxygen has a crucial role in artemisinin-induced apoptosis (31). When reacting with iron, artemisinin produces large amounts of free radicals (32). Increases in intracellular ROS lead to the opening of the mitochondrial permeability transition pore (MPT), thus increasing the mitochondrial membrane permeability, resulting in a reduction of the Δψm. ROS can trigger and accelerate the opening of the MPT, which in turn promotes the generation of ROS (33,34). This feedback mechanism leads to a self-amplifying effect of ROS; thus, the opening of the MPT triggers an irreversible decrease of Δψm, leading to cell apoptosis. The present study found that artemisinin can induce the generation of ROS in GBC-SD and NOZ cells, along with the collapse of Δψm and activation of caspase-3, a key executioner of apoptosis. These results demonstrated that artemisinin exerts its anti-cancer effects by activating the ROS-mediated mitochondrial apoptotic pathway.
In conclusion, the present study showed that artemisinin can inhibit the proliferation of GBC-SD and NOZ cells by generating ROS. It also triggers G1-phase arrest through upregulation of p16 protein expression and downregulation of CDK4 and cyclin D1 expression, as well as downregulation of ERK1/2. The ROS generated by artemisinin activate mitochondrial-mediated apoptosis. All of these findings suggested that artemisinin may be used as a novel drug for gallbladder cancer, which is facilitated by its previous approval for pharmaceutical use.